ICUCW — SeaStar Medical Holding Corporation

SeaStar Medical Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: Reported at $183,000 for Q3 2025, up from $68,000 in Q3 2024. The company anticipates full-year revenue exceeding $1 million.
• Gross Profit Margin: Approximately 92% for Q3, reflecting the first full quarter of cost of goods sold for Quellimmune product sales.
• Operating Expenses: Decreased to $3.7 million in Q3 2025 from $4.5 million in Q3 2024, primarily due to reduced consulting and personnel costs.
• Net Loss: Approximately $3.5 million, or $0.13 per share, compared to a net loss of $4.5 million, or $1.10 per share, in the prior year.
• Cash Position: $13.8 million as of September 30, 2025, up from $1.8 million at the end of 2024, bolstered by a $12.4 million capital raise.

2. Strategic Updates and Business Highlights

• Customer Base Expansion: Added three top-ranked children's medical centers, bringing the total to 10 active commercial pediatric hospitals.
• Clinical Data: Positive survival results from the Quell immune therapy were presented at a symposium, showing a 76% survival rate at 60 days and 71% at 90 days for 21 pediatric patients.
• Clinical Trials: Completed an interim analysis for the neutralized AKI pivotal trial, with plans to increase enrollment from 200 to 339 patients based on recommendations from the data safety monitoring board (DSMB).
• New Trials: Launched a neutralized CRS trial targeting patients with chronic systolic heart failure, aiming to enroll 20 patients.

3. Forward Guidance and Outlook

• Revenue Expectations: Anticipating over $1 million in revenue for the full year 2025, with early Q4 sales already exceeding Q3 totals.
• Market Potential: The U.S. market for Quellimmune therapy is estimated at $100 million, with expectations of capturing a significant share.
• Enrollment Goals: Committed to reaching the new target of 339 patients in the AKI trial by December 2026, with ongoing efforts to activate additional clinical sites.

4. Bad News, Challenges, or Points of Concern

• Enrollment Challenges: The requirement for a registry has slowed site additions, impacting the speed of enrollment in clinical trials.
• Variable Sales: Revenue remains somewhat unpredictable, with fluctuations noted from quarter to quarter.
• Efficacy Signal: While an encouraging signal of clinical benefit was observed in the AKI trial, it was not statistically significant at the original sample size, necessitating an increase in enrollment.

5. Notable Q&A Insights

• Enrollment Update: As of the call, 146 patients were enrolled in the AKI trial, with 17 sites activated and plans to activate eight more.
• Trial Timeline: The new CRS trial is in early stages, with expectations to complete enrollment within a year, pending site activations.
• Revenue Clarification: Confirmed that the company is on track for over $1 million in revenue for 2025, addressing concerns about revenue variability.

This summary encapsulates the key points from the earnings call, highlighting both the progress and challenges faced by SeaStar Medical as they navigate their growth and clinical initiatives.